Eli Lilly and Company (LLY) and Centessa Pharmaceuticals plc (CNTA) announced a definitive agreement for Lilly to acquire Centessa. Lilly will acquire all of the issued and to be issued share capital of Centessa for $38.00 in cash per share plus one non-transferrable CVR that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of milestones, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion. The CVR represents an additional potential aggregate equity value of approximately $1.5 billion.
"Centessa is at the forefront of orexin science, and we've built a potential best-in-class portfolio of OX2R agonists with a level of depth and breadth that could help redefine what's possible in neuroscience," said Mario Alberto Accardi, CEO of Centessa.
In pre-market trading on NasdaqGS, Centessa shares are up 46.96 percent to $40.53.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.